Last Updated : July 24, 2024
Details
Generic Name:
baloxavir marboxil
Project Status:
Not filed
Therapeutic Area:
Influenza
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Xofluza
Project Line:
Reimbursement Review
Project Number:
NS0016-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
Treatment of uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are otherwise healthy or at high risk of developing influenza complications.
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : July 24, 2024